Baili Tianheng announced that the company's self-developed phase III randomized controlled clinical trial of injectable t-Bren combined with pertuzumab for the new adjuvant treatment of HER2-positive breast cancer compared with docetaxel, carboplatin+trastuzumab, and pertuzumab has recently completed the first patient enrollment.

Baili Tianheng announced that the company's self-developed phase III randomized controlled clinical trial of injectable t-Bren combined with pertuzumab for the new adjuvant treatment of HER2-positive breast cancer compared with docetaxel, carboplatin+trastuzumab, and pertuzumab has recently completed the first patient enrollment.